Hot Investor Mandate: USA-Based Family Office Invests in Pre-Seed to Series A Companies in the Fields of CNS and Neurodegenerative Diseases

18 Mar

A family office based in the US invests in pre-seed, seed and series A stage investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million. The firm may invest at later stages on a case-by-case basis. The firm invests across precision neuroscience, life sciences platforms, aerospace, digital deep tech, and climate tech. The firm prefers to invest in companies in conjunction with strong investment syndicate partners. The firm is open to opportunities worldwide. 
 
The firm’s life sciences funds early-stage companies across neurodegeneration, psychiatry and neurotech and also funds life science platform opportunities that raise the tide towards precision neuro. The firm invests across modalities. 
 
The firm invests in privately held companies and backs top scientists, who are pursuing breakthrough approaches rather than traditional. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: VC Firm With China Headquarters Seeks Innovative Therapeutics, Devices, and Diagnostics Companies Across the Globe

18 Mar

A venture capital firm with main offices in China manages both RMB and USD funds. On average, the initial size of investment is in the $1-6M range, but the firm has the capacity to invest more in companies they identify as a strong fit. The firm also manages innovation centers in China focusing on different special areas in Life Sciences and medical devices. With many years of operating experience of international medical technology incubators, the firm looks to tailor its services to help portfolio companies reaching key value-added milestones. The firm will consider opportunities based in China and around the globe. The firm actively supports global companies to fast land China market by leveraging the fund’s connections with leading hospitals and KOLs in China. 
 
The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, AI, and Biotechnology R&D Services. The firm is opportunistic in terms of sub-sector and indication and is willing to consider companies targeting orphan indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. In terms of therapeutics, the firm will look at products in pre-clinical stages. Regarding medical devices and diagnostics, the firm will invest at any stage of development. 
 
The firm will invest in privately held companies only, and the firm can participate as either lead or co-investor. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: USA-Based VC Firm Invests in All Life Science and HealthTech Sectors Across Pre-Seed, Seed, and Series A Rounds

18 Mar

A venture capital fund based in the US has invested the majority of its portfolio in the Life Sciences and HealthTech sectors. The firm plans to invest in two-or-three new portfolio companies and make one or two additional follow-on investments. The firm typically makes Pre-Seed, Seed and Series A investments ranging in size from $250K to $1M, and its largest total investment (including follow-ons) in any one company is $3.25M.  
 
The firm invests primarily in the Life Sciences and HealthTech sectors and in a wide range of sub-sectors within those sectors. The firm is sector and subsector agnostic and is open to evaluating different types of technologies. 
 
The firm invests in companies with growth-minded founders with proven track records, defensible market positions, and the ability to be positive cash-flow within 12-24 months. The firm is minority-owned and is committed to managing a diverse portfolio of companies with the potential to deliver above-average returns, including companies with minority, female and SEDI founders. The firm is an active investor that can provide valuable de-risking strategic and operational guidance and support through its venture studio, which helps portfolio companies reduce the risk of costly mistakes, get to market sooner and scale faster. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: China-Based VC Firm Invests in Early-Stage Therapeutics and Digital Health Companies Interested in China Market Entry 

18 Mar

Founded in 2019, a Chinese venture capital firm is specialized in the growth-stage life science investments and IT area. Currently, the firm has 300M RMB assets under management. While generally being flexible on the allocation size, the firm typically makes investments ranging from 10-60 MM RMB (~1.4-8.5 MM USD). 
 
The firm has strong interest in investing novel pharmaceuticals, including orphan drugs. Also, the firm is open to digital health, especially the ones has big data application in life science area. So far, the firm has no interest in diagnostics nor medical devices products. 
 
The firm prefers companies with a China Angle, especially the ones open to register an entity in China. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Investor Panelists at RESI Europe 2025

18 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Life Science Nation (LSN) team is preparing for next week’s RESI Europe conference in Barcelona, where life science and healthcare innovators will connect with a global network of investors. With a curated agenda featuring six panels, attendees will gain key insights into emerging investment trends and strategies shaping the industry.

This year’s panels will cover Medical Devices, Digital Health, Corporate VC, Cross-Border Investments, Seed Funds, and Therapeutics Innovations. LSN has assembled a distinguished lineup of panelists representing diverse investment groups, from corporate venture capitalists to early-stage investors and sector specialists. These experts will share their approaches to evaluating startups, their perspectives on the evolving investment landscape, and their insights into fostering successful partnerships. As a truly international event, RESI Europe will bring together investors from across the globe, creating opportunities for cross-border collaboration and meaningful networking.

RESI panels are designed to facilitate constructive dialogue between investors and fundraising CEOs. Attendees will receive tactical advice on capital raising and partnership development, helping them refine their strategies and accelerate their fundraising efforts. These must-attend discussions offer founders and executives direct access to investors, providing an invaluable platform to expand their networks and gain actionable insights.

Join the panelists below at RESI Europe and take the next step in your fundraising journey.

Carla-Benichou
Carla Benichou
Senior Investment Analyst
RV Invest GmbH 		Jorge-Blasco
Jorge Blasco
Venture Partner (Spain)
Lumo Labs 		Nils-Bottler
Nils Bottler
Principal (Berlin)
Angelini Ventures
Matthieu-Coutet
Matthieu Coutet
Partner, Biovelocita Strategy
Sofinnova Partners 		Geoffrey-D'hondt
Geoffrey D’hondt
Investment Director
Heran Partners 		Jordi-Ferrer
Jordi Ferrer
Healthcare Investment Director
Ship2B Ventures
Lina-Gaydarova
Lina Gaydarova
Investment Manager
Novaterra 		Simon-Hua
Simon Hua
Chairman
BioMetas 		Santiago-Lozano
Santiago Lozano
Healthtech Funds Director
Clave Capital
Jim-McGough
Jim McGough
Managing Partner
Mid Atlantic Bio Angels 		Erki-Mölder
Erki Mölder
Managing Partner
Verge Health Tech Fund 		Daniel-OMahony
Daniel O’Mahony
Partner
Seroba Life Sciences
Luis-Pareras
Luis Pareras
Managing Partner
Invivo Partners 		Sanchita-Pasi
Sanchita Pasi
Investor
EQT Life Sciences 		William-Pay
William Pay
Venture Partner
Winhealth Pharma
Laura-Rodriguez
Laura Rodriguez
Partner
Invivo Partners 		Artemy-Shumskiy
Artemy Shumskiy
Senior Associate
LongeVC 		Florence-Thueux
Florence Thueux
President & CEO
M2Care
Louise-Warme
Louise Warme
Head of We Venture Capital
We Venture Capital




Insights from the Investor Fireside Chat on Life Science Fundraising

18 Mar

By Joey Wong, Director of Investor Research, Hong Kong BD, LSN

Joey-New-HeadshotHosted by Life Science Nation (LSN), co-moderated by Labiotech.eu, and sponsored by ShareVault, last Thursday’s Investor Fireside Chat brought together four active investors in the life sciences and healthcare sectors. Each panelist shared insights from their unique investment focus and fund background, offering perspectives on key investment trends and the 2025 landscape.

A central theme that emerged was cautious optimism in early-stage life science and healthcare fundraising. While investors have remained highly conservative in recent years, there is still dry powder available, and some are considering deploying capital to generate returns. However, overall sentiment remains cautious, with investors seeking greater certainty about capital allocation. Panelists emphasized that companies should plan their runway carefully, as raising funds between seed and Series A may take longer than anticipated. Additionally, securing continued support from existing investors was highlighted as a critical factor in navigating the current fundraising environment.

When asked for advice, panelists underscored the importance of capital efficiency. They encouraged companies to focus on fundamentals, set clear milestones, be strategic about pipeline expansion, and extend their runway as much as possible. One panelist suggested planning for at least 12 to 30 months of runway. While high valuations are always appealing, the panelists advised founders to recognize today’s challenges and seize investment opportunities when available – after all, cash is king, and survival is key.




Interview with RESI JPM Sponsor, Bullfrog AI 

13 Mar

By Caitlin Dolegowski, Marketing Manager, LSN

CaitiBullfrog AI is at the forefront of integrating artificial intelligence into drug development, helping biotech and pharma companies extract meaningful insights from complex data. Toby Sayre shares how the company’s AI-driven approach enhances decision-making, accelerates therapeutic innovation, and improves success rates. In this interview, he discusses Bullfrog AI’s technology, its role in shaping the future of drug development, and the company’s experience at RESI.

Secure your sponsorship or exhibitor package today. Contact the LSN Business Development Team to find the best fit for your brand and maximize your impact at RESI in 2025.

← Older Entries
Newer Entries →